Alzheimer Disease Clinical Trial
— EOAD-SubtypeOfficial title:
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | March 31, 2022 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility |
- Inclusion criteria for patients with Alzheimer's disease (AD): 1. Meet criteria for AD. 2. Meet clinical criteria for either typical amnestic AD or variant phenotypes of early-onset (EOAD, or "Type 2 AD"). 3. Mild-moderate dementia severity 4. Sufficient English fluency to complete neuropsychological testing in English. 5. Ability to provide consent for participation, or willingness to provide assent and a legally-authorized representative willing to provide surrogate consent. 6. Availability of a caregiver informant for participation - Exclusion criteria for patients with Alzheimer's disease (AD): 1. Complicating medical illnesses. 2. Significant primary visual impairments. 3. Major psychiatric illness not due to the dementia. 4. Confounding medications. - Inclusion criteria for control participants: 1. Score 28/30 or higher on the Folstein Mini-Mental Status Exam. 2. Age 40-85 years old 3. Able to provide consent for participation and express willingness to participate in one-year follow-up visits. 4. Have sufficient English fluency to complete neuropsychological testing in English. - Exclusion criteria for control participants: 1. Complicating medical illnesses. 2. Significant primary visual impairments. 3. Major psychiatric illness not due to the dementia. 4. Confounding medications. |
Country | Name | City | State |
---|---|---|---|
United States | UCLA Department of Neurology | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | National Institute on Aging (NIA), University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Alzheimer's disease Subtype | Neuropsychological testing results for use in a two-stage multivariate diagnostic method that combines the (weighted) test results in order to best discriminate Type 2 AD and typical AD. | Performed at baseline | |
Secondary | Change in overall Neurological profile | Change in performance on neurological tasks between baseline visit and follow-up visit. | Performed at baseline and 1-year follow-up visit | |
Secondary | Brain atrophy in MRI - Magnetic Resonance Imaging of the brain | Images from initial MRI scan taken at baseline visit will be analyzed for atrophy and white matter tract integrity | Performed at baseline visit | |
Secondary | Change in overall Neuropsychological profile | Change in neuropsychological performance over time. | Performed at baseline and 1-year follow-up visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |